sars cov 2 — grants

Sort

8,912 grants matching “sars cov 2”

MPOPHC: Integrating human risk perception and social processes into policy responses in an epidemiological model

$1,344,200

Brian Beckage · University Of Vermont & State Agricultural College · · FY2024 · MPS

Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases

$1,343,818

T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK

Recombinant Virus Vaccines

$1,342,916

Bernard Moss · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012

$1,341,481

Mark Joseph Mulligan · New York University School Of Medicine · UM1 · FY2021 · AI

Interactions of SARS-CoV-2 N-protein

$1,341,376

Peter Schuck · National Institute Of Biomedical Imaging And Bioengineering · ZIA · FY2024 · EB

NIEHS Knock Out Mouse Core (KOMC) Annual Report

$1,338,679

Manas Ray · National Institute Of Environmental Health Sciences · ZIC · FY2021 · ES

Facility Management, Maintenance and Operation Core

$1,338,439

Raymond Paul Goodrich · Colorado State University · UC7 · FY2023 · AI

Improving precision health approaches through large-scale EHRs and biobanks

$1,338,175

Joshua Denny · National Human Genome Research Institute · ZIA · FY2022 · HG

CoVPN Cross-Protocol Analyses

$1,334,886

Peter B. Gilbert · Fred Hutchinson Cancer Research Center · UM1 · FY2022 · AI

Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

$1,334,000

Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Evaluation of Novel Technologies to Improve Clinical Management of Celiac Disease: The GLUTECH Trial

$1,333,964

Benjamin Lebwohl · Columbia University Health Sciences · U01 · FY2024 · DK

Epidemiology, transmission and immunology of COVID-19 in nursing home residents

$1,332,423

David H Canaday · Case Western Reserve University · R01 · FY2021 · AI

Clinical and Informatics Research on Large Clinical Databases

$1,331,015

Clement McDonald · National Library Of Medicine · ZIA · FY2022 · LM

Diagnosis of MIS-C in febrile children

$1,329,345

Audrey Ragan Odom John · Children'S Hosp Of Philadelphia · R33 · FY2023 · HD

Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trial

$1,328,303

Julio Alonso Chirinos Medina · University Of Pennsylvania · U01 · FY2021 · TR

Culturally-targeted communication to promote SARS-CoV-2 antibody testing in saliva: Enabling evaluation of inflammatory pathways in COVID-19 racial disparities

$1,326,405

Todd William Lucas · Michigan State University · U01 · FY2020 · CA

HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3

$1,324,786

Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2022 · AI

Determining the Effects of Sequence Variation on Membrane Fusion Proteins through High-Resolution Characterization of Protein Energy Landscapes

$1,323,081

Alanna Schepartz · University Of California-Berkeley · · FY2023 · MPS

ECHO Renewal for the CANOE Study Cohort

$1,320,521

Tina V Hartert · Vanderbilt University Medical Center · UG3 · FY2023 · OD

Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapies

$1,318,233

Cynthia E Dunbar · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL

Cherokee Nation Native AmericanResearch Center for Health

$1,317,488

Sohail Imran Khan · Cherokee Nation · S06 · FY2022 · GM

NIEHS Cryo-EM Core Facility

Clinical and biomarker studies in Alzheimer's disease and related disorders

The Effects of Oxygen Therapy on Mouse Hepatitis Coronavirus Induced Pneumonia

Signal Transduction In B Lymphocytes: Identification Of Key Signaling Molecules

MPOPHC: Integrating human risk perception and social processes into policy responses in an epidemiological model

Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases

Recombinant Virus Vaccines

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012

Interactions of SARS-CoV-2 N-protein

NIEHS Knock Out Mouse Core (KOMC) Annual Report

Facility Management, Maintenance and Operation Core

Improving precision health approaches through large-scale EHRs and biobanks

CoVPN Cross-Protocol Analyses

Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Evaluation of Novel Technologies to Improve Clinical Management of Celiac Disease: The GLUTECH Trial

Epidemiology, transmission and immunology of COVID-19 in nursing home residents

Clinical and Informatics Research on Large Clinical Databases

Diagnosis of MIS-C in febrile children

Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trial

Culturally-targeted communication to promote SARS-CoV-2 antibody testing in saliva: Enabling evaluation of inflammatory pathways in COVID-19 racial disparities

HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3

Determining the Effects of Sequence Variation on Membrane Fusion Proteins through High-Resolution Characterization of Protein Energy Landscapes

ECHO Renewal for the CANOE Study Cohort

Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapies

Cherokee Nation Native AmericanResearch Center for Health